BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for V Jayaprakash

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Quinazoline derivatives as selective CYP1B1 inhibitors.EBI
Birla Institute of Technology
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.EBI
Birla Institute of Technology
A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.EBI
University of Kwazulu-Natal
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.EBI
Birla Institute of Technology
Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis.EBI
Weill Medical College of Cornell University
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.EBI
Birla Institute of Technology
Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.EBI
Institute of Technology
Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.EBI
Institute of Technology
Pyrazoline-based mycobactin analogues as MAO-inhibitors.EBI
Institute of Technology
A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.EBI
Universita degli Studi di Bari "Aldo Moro"
Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.EBI
Birla Institute of Technology
A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.EBI
Birla Institute of Technology
Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.EBI
De Montfort University
Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1.EBI
Birla Institute of Technology
Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.EBI
Birla Institute of Technology
Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein.BDB
Smithkline Beecham Pharmaceuticals